Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA Big Molecule WatchOn July 24, 2026, Outlook Therapeutics, Inc.OphthalmologyRead full story pharminent July 31, 2026 (Last updated: August 3, 2026) Big Molecule Watch On July 24, 2026, Outlook Therapeutics, Inc. Ophthalmology Read full story Post navigation Previous: J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyoutNext: Novo setback casts doubt on a new way to treat heart disease Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026